Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 2
2015 1
2017 5
2019 2
2020 1
2021 2
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

14 results
Results by year
Filters applied: . Clear all
Page 1
Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling.
Bluemn EG, Coleman IM, Lucas JM, Coleman RT, Hernandez-Lopez S, Tharakan R, Bianchi-Frias D, Dumpit RF, Kaipainen A, Corella AN, Yang YC, Nyquist MD, Mostaghel E, Hsieh AC, Zhang X, Corey E, Brown LG, Nguyen HM, Pienta K, Ittmann M, Schweizer M, True LD, Wise D, Rennie PS, Vessella RL, Morrissey C, Nelson PS. Bluemn EG, et al. Among authors: nyquist md. Cancer Cell. 2017 Oct 9;32(4):474-489.e6. doi: 10.1016/j.ccell.2017.09.003. Cancer Cell. 2017. PMID: 29017058 Free PMC article.
Selective androgen receptor modulators activate the canonical prostate cancer androgen receptor program and repress cancer growth.
Nyquist MD, Ang LS, Corella A, Coleman IM, Meers MP, Christiani AJ, Pierce C, Janssens DH, Meade HE, Bose A, Brady L, Howard T, De Sarkar N, Frank SB, Dumpit RF, Dalton JT, Corey E, Plymate SR, Haffner MC, Mostaghel EA, Nelson PS. Nyquist MD, et al. J Clin Invest. 2021 May 17;131(10):e146777. doi: 10.1172/JCI146777. J Clin Invest. 2021. PMID: 33998604 Free PMC article.
Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress.
Nyquist MD, Corella A, Coleman I, De Sarkar N, Kaipainen A, Ha G, Gulati R, Ang L, Chatterjee P, Lucas J, Pritchard C, Risbridger G, Isaacs J, Montgomery B, Morrissey C, Corey E, Nelson PS. Nyquist MD, et al. Cell Rep. 2020 May 26;31(8):107669. doi: 10.1016/j.celrep.2020.107669. Cell Rep. 2020. PMID: 32460015 Free PMC article.
Selective androgen receptor modulators activate the canonical prostate cancer androgen receptor program and repress cancer growth.
Nyquist MD, Ang LS, Corella A, Coleman IM, Meers MP, Christiani AJ, Pierce C, Janssens DH, Meade HE, Bose A, Brady L, Howard T, De Sarkar N, Frank SB, Dumpit RF, Dalton JT, Corey E, Plymate SR, Haffner MC, Mostaghel EA, Nelson PS. Nyquist MD, et al. J Clin Invest. 2021 Jun 15;131(12):e151719. doi: 10.1172/JCI151719. J Clin Invest. 2021. PMID: 34128479 Free PMC article. No abstract available.
14 results